Breast Dose in Young Women Treated for Hodgkin Lymphoma Between 2007 and 2018: A Single Institutional Study

Purpose/Objective(s)Women receiving supradiaphragmatic radiotherapy (RT) for Hodgkin Lymphoma (HL) aged ≤ 36y have a greater risk of breast cancer (BC) than the general population. Although RT fields have reduced in recent years, breast tissue (BT) is unavoidably irradiated in many women. Despite the long-term risk, dose to BT is not routinely nor consistently reported: published studies report inconsistent breast dose metrics, or only point...